Program Description & Educational Objectives
In this activity, a panel of experts in cardiology discusses optimal management of patients with acute coronary syndrome requiring antiplatelet therapy.
Upon completion of this activity, participants will be able to:
- Apply data from evidence-based guidelines and clinical trials on antiplatelet therapy for patients with ACS, with the goal of improving patient outcomes and managing risks of ischemic events
- Properly tailor antiplatelet therapy to patients’ specific needs, including individuals with comorbid conditions such as diabetes, hyperlipidemia/dyslipidemia, and hypertension
- Evaluate data on emerging antiplatelet therapies and their possible role in patients with ACS
Target Audience
This activity has been designed to meet the educational needs of cardiologists, internal medicine specialists, and family practice physicians, as well as other clinicians involved in managing patients with acute coronary syndrome.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Internet
Release and Expiration Dates: January 04, 2010 - January 03, 2011
Time to Complete: 45 minutes
Faculty & Disclosure
Course Director and Moderator
Deepak L. Bhatt, MD, MPH
Chief of Cardiology
VA Boston Healthcare System
Director, Integrated Interventional Cardiovascular Program
Brigham and Women’s Hospital and the VA Boston Healthcare System
Senior Investigator, TIMI Study Group
Boston, Massachusetts
Deepak L. Bhatt, MD, MPH,
has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Bristol-Myers Squibb Company; Eisai Inc.; Ethicon Inc.; sanofi-aventis; and The Medicines Company.
Interviewees
Robert A. Harrington, MD
Professor of Medicine
Division of Cardiology
Duke University Hospital
Director, Cardiovascular Clinical Trials
Duke Clinical Research Institute
Durham, North Carolina
Robert A. Harrington, MD,
has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Portola Pharmaceuticals, Inc.; sanofi-aventis; and Schering-Plough Corporation.
Grant/Research Support from AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Merck & Co., Inc.; Schering-Plough Corporation; and The Medicines Company.
Other Financial or Material Support from The Medicines Company supporting the Heart.Org activity.
Benjamin M. Scirica, MD, MPH
TIMI Study Group, Cardiovascular Division
Brigham and Women's Hospital
Boston, Massachusetts
Benjamin M. Scirica, MD, MPH,
has a financial interest/relationship or affiliation in the form of:
Consultant for Cogentus Pharmaceuticals, Inc.
Grant/Research Support from AstraZeneca Pharmaceuticals LP; Daiichi Sankyo, Inc.; and Novartis Pharmaceuticals Corporation.
Honorarium from Novartis Pharmaceuticals Corporation.
Advisory Board for AstraZeneca Pharmaceuticals LP and Novartis Pharmaceuticals Corporation.
Content Director
Annette Wiggins
PVI, PeerView Institute for Medical Education, Inc.
Annette Wiggins
currently has no financial interests/relationships or affiliations in relation to this activity.
All additional planning committee members, PVI, PeerView Institute for Medical Education, Inc. staff, and Purdue University School of Pharmacy staff have no relationships to disclose.
Sponsorship, Credit & Support
Physicians
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Purdue University School of Pharmacy and PVI, PeerView Institute for Medical Education. Purdue University School of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University School of Pharmacy designates this educational activity for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses
Purdue University Continuing Nursing Education is approved as a provider of continuing nursing education by the Indiana State Nurses Association. ISNA is accredited as an approver of continuing education in nursing by the Commission on Accreditation of the American Nurses Credentialing Center. Code #CNEP-09-23.
This program has been approved for 1.0 contact hour(s).
Pharmacists
Purdue University School of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Program Number (UPN): 0018-9999-09-244-H01-P, 0.75 contact hours (0.075 CEUs).
This activity is supported by an educational grant from 
